2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
02:00 p.m. - 03:30 p.m.
MCCNO - 353-355
Technology and Procedures, Assays, Cell Expansion, Treatment Considerations, Combination Therapy, Biological Therapies, Antibody Therapy, Natural Killer (NK) Cell Therapies, Chimeric Antigen Receptor, Biological Processes, Immune Mechanism, Diseases, Immunology, GVHD, Myeloid Malignancies, Acute Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, Study Population, Animal Model
PAPER

285 CAR-stick enables localized interleukin-12 delivery to enhance CD70 CAR-NK cell therapy for acute myeloid leukemia

Remy Dulery, MD, PhD, Fuguo Liu, PhD2, Xingyu Deng3, Grace Caroline Birch, PhD4, Eden Bobilev5, Sara Piccinelli6, Maily Nyugen7, Alaa Kassim Ali, PhD8, Shaobo Yang9, Mila Stanojevic10, Andreia Maia, MS, PhD11, Michal Sheffer, PhD12, Mark Cerasoli13, Roman Shapiro, MD14, Mahasweta Gooptu, MD15, John Koreth, MD,MBBS,PhD,DPhil16, Catherine J. Wu, MD17, Daniel J DeAngelo, MD, PhD18, Andrew A. Lane, MD, PhD19, Robert J Soiffer, MD20, Jerome Ritz, MD21, Mubin Tarannum22, Rizwan Romee, MD23
1 Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States
2 Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States
3 Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States
4 Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States
5 Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States
6 Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States
7 Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States
8 Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States
9 Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States
10 Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States
11 Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States
12 Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States
13 Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States
14 Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States
15 Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States
16 Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States
17 Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States
18 Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States
19 Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States
20 Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States
21 Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States
22 Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States
23 Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States

Background. Relapsed or refractory acute myeloid leukemia (AML) remains associated with poor outcomes. The clinical development of CAR T-cell therapies targeting CD123 or CD33 has been limited by short-lived responses and on-target toxicity to normal hematopoietic progenitors, resulting in prolonged cytopenias. CD70 therefore represents an attractive alternative target because it is expressed on most AML blasts while being absent from normal hematopoietic stem cells. Cytokine-induced memory-like (CIML) NK cells represent a promising off-the-shelf cellular therapy with an excellent safety profile. Interleukin-12 (IL-12) is a highly potent cytokine that enhances NK-cell activation, persistence, and cytotoxicity, but its clinical development has been hindered by systemic toxicity. To overcome these limitations, we developed CAR-STICK (Spatial Targeting and Interleukin-Coated Killing), a first-in-class platform for spatial cytokine delivery. Following CAR activation, physiological CD62L (L-selectin) shedding releases a CD123-targeted IL-12 fusion protein that binds CD123 on nearby cells. Unlike CD123-directed CAR therapies, CAR-STICK uses CD123 solely to retain IL-12 locally rather than to mediate cytotoxicity. We hypothesized that CAR-STICK would enhance anti-leukemia efficacy while minimizing systemic IL-12 exposure.

 

Methods. CAR constructs targeted CD70 using the CD27 ectodomain and incorporated CD8 transmembrane and 4-1BB/CD3ζ signaling domains. STICK was generated by fusing IL-12 to an anti-CD123 single-chain variable fragment (scFv) through a flexible linker and anchoring the fusion protein to CD62L. Peripheral blood-derived CIML NK cells were transduced using an optimized baboon envelope-pseudotyped lentiviral platform. Free IL-12 in culture supernatants was quantified by ELISA. Anti-tumor activity, including cytotoxicity (Annexin V/7-AAD) and bystander NK-cell activation (CD107a and IFNγ), was evaluated by flow cytometry following 24h co-culture of untransduced CIML NK or CAR-CIML NK cells with CD70-positive AML cell lines. In vivo efficacy was assessed in NSG-Tg(Hu-IL-15) mice engrafted with luciferase-expressing OCI-AML3 leukemia using serial bioluminescence imaging and survival analysis.

 

Results. High transduction efficiency was achieved across all CAR constructs (45–92%), with reproducible construct expression. STICK fusion protein was effectively released through CD62L shedding following both PMA-ionomycin stimulation and CAR engagement during co-culture with CD70-positive AML cells. The released STICK fusion protein selectively coated CD123-expressing AML cells (OCI-AML2 and OCI-AML3), confirming successful activation-dependent spatial localization. In contrast to constitutively IL-12-secreting CAR-NK cells, CAR-STICK maintained minimal free IL-12 in culture supernatants both at baseline (0.00005 vs. 1.02 ng/mL, p=0.002) and following AML co-culture (0.13 vs. 3.16 ng/mL, p=0.002). CAR-STICK demonstrated cytotoxicity comparable to IL-12-secreting CAR-NK cells while outperforming conventional CD70 CAR-NK cells across multiple CD70-positive AML cell lines, including OCI-AML2, OCI-AML3, and NOMO-1, irrespective of TP53 mutation status. CAR-STICK also enhanced NK-cell activation and promoted bystander NK-cell activation, as demonstrated by increased CD107a degranulation and IFNγ production. Importantly, CAR-STICK did not induce cytotoxicity against CD123-positive, CD70-negative KG1a cells, indicating that CD123 binding alone is insufficient to trigger cytotoxicity. In an OCI-AML3 xenograft model, CAR-STICK significantly improved leukemia control compared with untransduced CIML NK cells (p=0.020) and prolonged median survival to 35.5 days compared with 31 days for both CD70 CAR-NK-IL-12 cells (log-rank p=0.007) and CD70 CAR-NK cells (p=0.009).

Conclusions. CAR-STICK is a first-in-class platform for localized cytokine delivery that combines the potent immunostimulatory effects of IL-12 with spatial targeting to minimize systemic exposure. By exploiting physiological CD62L shedding, CAR-STICK retains IL-12 locally, enhancing the efficacy of CD70-directed CAR-NK cells and promoting bystander NK-cell activation. Our findings demonstrate the engineering feasibility and therapeutic potential of this approach, supporting its clinical translation toward first-in-human evaluation in patients with relapsed or refractory AML. Beyond AML, the CAR-STICK platform could be adapted to additional hematologic malignancies.

Remy Dulery, MD, PhD: Kite / Gilead - Other (including travel support); Ligue Contre le Cancer - Research Funding; Philippe Foundation - Research Funding; Philippe Foundation - Research Funding; Ligue Contre le Cancer - Research Funding